Oncology

Five things for pharma marketers to know: Friday, May 20, 2016

Five things for pharma marketers to know: Friday, May 20, 2016

By

Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices

Five things for pharma marketers to know: Wednesday, May 18, 2016

Five things for pharma marketers to know: Wednesday, May 18, 2016

By

Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year

Novartis splits pharma division, shakes up management team

Novartis splits pharma division, shakes up management team

By

Novartis breaks up pharmaceutical division and announces that David Epstein, CEO of Novartis Pharmaceuticals, will leave the company.

Novartis considers new sales model for experimental cancer therapy

Novartis considers new sales model for experimental cancer therapy

By

Using a med-tech strategy may help stem concern about CAR T-cell technology's complicated distribution and anticipated high prices, said Novartis exec.

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

By

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

By

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

How Watson for Oncology is advancing cancer care

How Watson for Oncology is advancing cancer care

By

IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.

Rolling with the Punches as Marketing Evolves

Rolling with the Punches as Marketing Evolves

Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

By

The drugmaker instead suggested using an economic model it developed.

Precision for Medicine acquires ACT Oncology

Precision for Medicine acquires ACT Oncology

By

The scientific services company expands its portfolio to include expertise in oncology clinical studies.

Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules

Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules

By

The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.

Drugmakers partner in immuno-oncology, to better capture market share

Drugmakers partner in immuno-oncology, to better capture market share

By

Manufacturers team up to study drug combinations, a strategy expected to advance the category.

Five things for pharma marketers to know: Friday, February 26, 2016

Five things for pharma marketers to know: Friday, February 26, 2016

By

Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO

Five things for pharma marketers to know: Friday, February 19, 2016

Five things for pharma marketers to know: Friday, February 19, 2016

By

Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Health economic and outcomes research datasets have rarely been integral to product development and communication plans.

Five things for pharma marketers to know: Wednesday, January 13, 2016

Five things for pharma marketers to know: Wednesday, January 13, 2016

By

Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup

Roche invests in oncology start-up

Roche invests in oncology start-up

By

The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.

Five things for pharma marketers to know: Wednesday, December 30, 2015

Five things for pharma marketers to know: Wednesday, December 30, 2015

By

Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles

Baxalta's oncology chief builds out company's third leg

Baxalta's oncology chief builds out company's third leg

By

David Meek has been charged with building an oncology arm that matches the company's existing strengths in hematology and immunology.

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

By

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Monday, December 14, 2015

Five things for pharma marketers to know: Monday, December 14, 2015

By

Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug

Five things for pharma marketers to know: Wednesday, December 9, 2015

Five things for pharma marketers to know: Wednesday, December 9, 2015

By

Pfizer reveals Ibrance pricing strategy; AMA call for DTC ban may resonate due to pricing debate; Baxalta's Vonvendi receives FDA approval

AstraZeneca to use mobile app in cancer trials

AstraZeneca to use mobile app in cancer trials

By

AstraZeneca plans to incorporate a mobile app that gathers information about side effects in three clinical trials studying an experimental combination therapy for ovarian cancer.

Five things for pharma marketers to know: Wednesday, November 25, 2015

Five things for pharma marketers to know: Wednesday, November 25, 2015

By

FDA advisers vote against BioMarin's Duchenne drug; the FDA approves Lilly's lung-cancer drug; criticism mounts for Pfizer's proposed deal with Allergan

Five things for pharma marketers to know: Tuesday, November 24, 2015

Five things for pharma marketers to know: Tuesday, November 24, 2015

By

Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease

Five things for pharma marketers to know: Tuesday, November 17, 2015

Five things for pharma marketers to know: Tuesday, November 17, 2015

By

Addyi off to a slow start; Dr. Robert Califf faces Senate committee on FDA nomination; FDA grants Opdivo Breakthrough Therapy Designation in kidney cancer

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

By

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Bristol-Myers Squibb turns to DTC to promote Opdivo

Bristol-Myers Squibb turns to DTC to promote Opdivo

By

The campaign marks the drugmaker's foray into oncology DTC advertising as it vies for market share against competing treatment Keytruda.

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

By

Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.

Diagnostics at the center of lung-cancer drug clash

Diagnostics at the center of lung-cancer drug clash

By

Oncologist perception of diagnostics may grow as immuno-oncology treatments move toward first-line use, drugmaker execs say.

OPINION

Email Newsletters